Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-109.48M |
| Operating Margin | 0.00% |
| Return on Equity | -142.90% |
| Return on Assets | -65.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.10 |
| Price-to-Book | 1.33 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $13.62M |
| Float | $11.84M |
| % Insiders | 0.97% |
| % Institutions | 46.77% |
Volatility is currently contracting
NEW YORK, July 9, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in July: July 14-15: Leerink Partners Therapeutics Forum. Erik Lundgren, Chief Executive Officer, Jason Tardio, President and Chief Operating Officer, Michael A.
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: June 15-16: H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.
– Late-Breaking Poster Introduces New Unified Statistical Analyses for Assessing Confirmed Disability Changes for Trials in Progressive Multiple Sclerosis – – Additional CALLIPER Data Further Highlight Vidofludimus Calcium's Favorable Safety and Tolerability Profile; Patient-Reported Outcomes Assessments Show No Negative Impact on Mood – NEW YORK, May 28, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the presentation of one late-breaking and two additional posters highlighting additional data from its phase 2 CALLIPER trial evaluating lead asset, nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, taking place May 27-29, 2026 in Charlotte, NC. All poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for potential commercialization. He succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining on the company's board of directors.
– Proven Leader with Deep Multiple Sclerosis Expertise; Played Key Role in the Launch of Ocrevus® – – Will Leverage Senior Global Executive and Commercial Experience to Support Immunic's Transition Toward a Commercial-Stage Multiple Sclerosis Company – NEW YORK, May 27, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as Chief Executive Officer, effective May 22, 2026, with employment beginning on June 1, 2026. Mr. Lundgren succeeds Daniel Vitt, Ph.D.
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including a background in multiple sclerosis and central nervous system markets.
– More Than 30 Years of Leadership Experience Across Biopharmaceutical Commercialization – – Played Key Role in the Launch and Commercial Success of Avonex® for Multiple Sclerosis – NEW YORK, May 19, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael "Mike" W. Bonney, a highly experienced biopharmaceutical executive and board leader, as Chair of its Board of Directors, effective May 16, 2026.
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as the company strengthens its leadership team and bolsters its balance sheet with a recently completed $200 million private financing. Along with the release of its first quarter financial results, the biotechnology company said it continues to advance its twin phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis (RMS).
– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.
